Dapagliflozin in focal segmental glomerulosclerosis: A combined human-rodent pilot study

American Journal of Physiology - Renal Physiology

Volumn 314, Issue 3, 2018, Pages F412-F422

  Rajasekeran, Harindra ^a,b   Reich, Heather N ^a   Hladunewich, Michelle A ^c   Cattran, Daniel ^a   Lovshin, Julie A ^a   Lytvyn, Yuliya ^a   Bjornstad, Petter ^d,e   Lai, Vesta ^a   Tse, Josephine ^a   Cham, Leslie ^a   Majumder, Syamantak ^f   Bowskill, Bridgit B ^f   Kabir, M Golam ^f   Advani, Suzanne L ^f   Gibson, Ian W ^g   Sood, Manish M ^h   Advani, Andrew ^f   Cherney, David Z I ^a,b  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^d UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF COLORADO DENVER   (United States)

^f ST MICHAEL'S HOSPITAL   (Canada)

^g UNIVERSITY OF MANITOBA   (Canada)

^h OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

Author keywords

FSGS; Nondiabetic CKD; SGLT2 inhibition

Indexed keywords

4 AMINOHIPPURIC ACID; DAPAGLIFLOZIN; INULIN; MESSENGER RNA; SODIUM GLUCOSE COTRANSPORTER 2; 2-(3-(4-ETHOXYBENZYL)-4-CHLOROPHENYL)-6-HYDROXYMETHYLTETRAHYDRO-2H-PYRAN-3,4,5-TRIOL; BENZHYDRYL DERIVATIVE; GLUCOSIDE; SGLT2 PROTEIN, RAT; SLC5A2 PROTEIN, HUMAN;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE; BODY WEIGHT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE MARKER; DOWN REGULATION; DRUG EFFECT; EFFECTIVE KIDNEY PLASMA FLOW; FEMALE; FOCAL GLOMERULOSCLEROSIS; GENE EXPRESSION; GLOMERULUS FILTRATION RATE; HEMATOCRIT; HUMAN; HUMAN TISSUE; KIDNEY BLOOD FLOW; KIDNEY FUNCTION; KIDNEY INJURY; KIDNEY PARENCHYMA; KIDNEY TISSUE; MALE; METABOLIC PARAMETERS; NEPHRECTOMY; NONHUMAN; OBESITY; PILOT STUDY; PRIORITY JOURNAL; PROTEIN URINE LEVEL; PROTEINURIA; RAT; SENSITIVITY ANALYSIS; SYSTOLIC BLOOD PRESSURE; TREATMENT RESPONSE; URINARY EXCRETION; VASOCONSTRICTION; ANIMAL; ARTERIOLE; DISEASE MODEL; GENETICS; KIDNEY; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; PROOF OF CONCEPT; SPRAGUE DAWLEY RAT; TIME FACTOR; TREATMENT OUTCOME; VASCULARIZATION;

ADULT; ANIMALS; ARTERIOLES; BENZHYDRYL COMPOUNDS; DISEASE MODELS, ANIMAL; FEMALE; GLOMERULAR FILTRATION RATE; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; GLUCOSIDES; HUMANS; KIDNEY; MALE; MIDDLE AGED; PILOT PROJECTS; PROOF OF CONCEPT STUDY; PROTEINURIA; RATS, SPRAGUE-DAWLEY; SODIUM-GLUCOSE TRANSPORTER 2; SODIUM-GLUCOSE TRANSPORTER 2 INHIBITORS; TIME FACTORS; TREATMENT OUTCOME; VASOCONSTRICTION;

EID: 85043593833     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00445.2017     Document Type: Article

References (45)

1. Advani A, Connelly KA, Yuen DA, Zhang Y, Advani SL, Trogadis J, Kabir MG, Shachar E, Kuliszewski MA, Leong-Poi H, Stewart DJ, Gilbert RE. Fluorescent microangiography is a novel and widely applicable technique for delineating the renal microvasculature. PLoS One 6: e24695, 2011. doi:10.1371/journal.pone.0024695.
2. Advani A, Kelly DJ, Advani SL, Cox AJ, Thai K, Zhang Y, White KE, Gow RM, Marshall SM, Steer BM, Marsden PA, Rakoczy PE, Gilbert RE. Role of VEGF in maintaining renal structure and function under normotensive and hypertensive conditions. Proc Natl Acad Sci USA 104: 14448–14453, 2007. doi:10.1073/pnas.0703577104.
3. Bjornstad P, Škrtić M, Lytvyn Y, Maahs DM, Johnson RJ, Cherney DZ. The Gomez equations and renal hemodynamic function in kidney disease research. Am J Physiol Renal Physiol 311: F967–F975, 2016. doi:10.1152/ajprenal.00415.2016.
4. Chen LH, Advani SL, Thai K, Kabir MG, Sood MM, Gibson IW, Yuen DA, Connelly KA, Marsden PA, Kelly DJ, Gilbert RE, Advani A. SDF-1/CXCR4 signaling preserves microvascular integrity and renal function in chronic kidney disease. PLoS One 9: e92227, 2014. doi:10. 1371/journal.pone.0092227.
5. Cherney D, Lund SS, Perkins BA, Groop PH, Cooper ME, Kaspers S, Pfarr E, Woerle HJ, von Eynatten M. The effect of sodium glucose cotransporter 2 inhibition with empagliflozin on microalbuminuria and macroalbuminuria in patients with type 2 diabetes. Diabetologia 59: 1860–1870, 2016. doi:10.1007/s00125-016-4008-2.
6. Cherney DZ, Konvalinka A, Zinman B, Diamandis EP, Soosaipillai A, Reich H, Lorraine J, Lai V, Scholey JW, Miller JA. Effect of protein kinase Cβ inhibition on renal hemodynamic function and urinary biomarkers in humans with type 1 diabetes: a pilot study. Diabetes Care 32: 91–93, 2009. doi:10.2337/dc08-1609.
7. Cherney DZ, Miller JA, Scholey JW, Bradley TJ, Slorach C, Curtis JR, Dekker MG, Nasrallah R, Hébert RL, Sochett EB. The effect of cyclooxygenase-2 inhibition on renal hemodynamic function in humans with type 1 diabetes. Diabetes 57: 688–695, 2008. doi:10.2337/db07-1230.
8. Cherney DZ, Perkins BA, Soleymanlou N, Maione M, Lai V, Lee A, Fagan NM, Woerle HJ, Johansen OE, Broedl UC, von Eynatten M. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation 129: 587–597, 2014. doi:10.1161/CIRCULATIONAHA.113.005081.
9. Cherney DZ, Perkins BA, Soleymanlou N, Xiao F, Zimpelmann J, Woerle HJ, Johansen OE, Broedl UC, von Eynatten M, Burns KD. Sodium glucose cotransport-2 inhibition and intrarenal RAS activity in people with type 1 diabetes. Kidney Int 86: 1057–1058, 2014. doi:10.1038/ki.2014.246.
10. de Mik SM, Hoogduijn MJ, de Bruin RW, Dor FJ. Pathophysiology and treatment of focal segmental glomerulosclerosis: the role of animal models. BMC Nephrol 14: 74, 2013. doi:10.1186/1471-2369-14-74.
11. Ferrannini E, Baldi S, Frascerra S, Astiarraga B, Heise T, Bizzotto R, Mari A, Pieber TR, Muscelli E. Shift to fatty substrate utilization in response to sodium-glucose cotransporter 2 inhibition in subjects without diabetes and patients with type 2 diabetes. Diabetes 65: 1190–1195, 2016. doi:10.2337/db15-1356.
12. Fischer PA, Bogoliuk CB, Ramirez AJ, Sánchez RA, Masnatta LD. A new procedure for evaluation of renal function without urine collection in rat. Kidney Int 58: 1336–1341, 2000. doi:10.1046/j.1523-1755.2000. 00290.x.
13. Fogo AB. Animal models of FSGS: lessons for pathogenesis and treatment. Semin Nephrol 23: 161–171, 2003. doi:10.1053/snep.2003.50015.
14. Fogo AB. Causes and pathogenesis of focal segmental glomerulosclerosis. Nat Rev Nephrol 11: 76–87, 2015. doi:10.1038/nrneph.2014.216.
15. Gallo LA, Ward MS, Fotheringham AK, Zhuang A, Borg DJ, Flem-ming NB, Harvie BM, Kinneally TL, Yeh SM, McCarthy DA, Koepsell H, Vallon V, Pollock C, Panchapakesan U, Forbes JM. Once daily administration of the SGLT2 inhibitor, empagliflozin, attenuates markers of renal fibrosis without improving albuminuria in diabetic db/db mice. Sci Rep 6: 26428, 2016. doi:10.1038/srep26428.
16. Gómez DM. Evaluation of renal resistances, with special reference to changes in essential hypertension. J Clin Invest 30: 1143–1155, 1951. doi:10.1172/JCI102534.
17. Han S, Hagan DL, Taylor JR, Xin L, Meng W, Biller SA, Wetterau JR, Washburn WN, Whaley JM. Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats. Diabetes 57: 1723–1729, 2008. doi:10.2337/db07-1472.
18. Har R, Scholey JW, Daneman D, Mahmud FH, Dekker R, Lai V, Elia Y, Fritzler ML, Sochett EB, Reich HN, Cherney DZ. The effect of renal hyperfiltration on urinary inflammatory cytokines/chemokines in patients with uncomplicated type 1 diabetes mellitus. Diabetologia 56: 1166– 1173, 2013. doi:10.1007/s00125-013-2857-5.
19. Har RL, Reich HN, Scholey JW, Daneman D, Dunger DB, Moineddin R, Dalton RN, Motran L, Elia Y, Deda L, Ostrovsky M, Sochett EB, Mahmud FH, Cherney DZ. The urinary cytokine/chemokine signature of renal hyperfiltration in adolescents with type 1 diabetes. PLoS One 9: e111131, 2014. doi:10.1371/journal.pone.0111131.
20. Heerspink HJ, Perkins BA, Fitchett DH, Husain M, Cherney DZ. Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications. Circulation 134: 752–772, 2016. doi:10.1161/CIRCULATIONAHA.116.021887.
21. Holtkamp FA, de Zeeuw D, Thomas MC, Cooper ME, de Graeff PA, Hillege HJ, Parving HH, Brenner BM, Shahinfar S, Lambers Heerspink HJ. An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function. Kidney Int 80: 282–287, 2011. doi:10.1038/ki.2011.79.
22. Jafar TH, Stark PC, Schmid CH, Landa M, Maschio G, Marcantoni C, de Jong PE, de Zeeuw D, Shahinfar S, Ruggenenti P, Remuzzi G, Levey AS; AIPRD Study Group. Angiotensin-Converting Enzymne Inhibition and Progression of Renal Disease. Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease. Kidney Int 60: 1131–1140, 2001. doi:10.1046/j.1523-1755.2001.0600031131.x.
23. Kapoor S, Rodriguez D, Riwanto M, Edenhofer I, Segerer S, Mitchell K, Wüthrich RP. Effect of sodium-glucose cotransport inhibition on polycystic kidney disease progression in PCK rats. PLoS One 10: e0125603, 2015. doi:10.1371/journal.pone.0125603.
24. Lytvyn Y, Škrtić M, Yang GK, Lai V, Scholey JW, Yip PM, Perkins BA, Cherney DZ. Plasma uric acid effects on glomerular haemodynamic profile of patients with uncomplicated type 1 diabetes mellitus. Diabet Med 33: 1102–1111, 2016. doi:10.1111/dme.13051.
25. Matsui K, Nagy-Bojarsky K, Laakkonen P, Krieger S, Mechtler K, Uchida S, Geleff S, Kang DH, Johnson RJ, Kerjaschki D. Lymphatic microvessels in the rat remnant kidney model of renal fibrosis: aminopep-tidase P and podoplanin are discriminatory markers for endothelial cells of blood and lymphatic vessels. J Am Soc Nephrol 14: 1981–1989, 2003. doi:10.1097/01.ASN.0000076078.50889.43.
26. Miller JA, Cherney DZ, Duncan JA, Lai V, Burns KD, Kennedy CR, Zimpelmann J, Gao W, Cattran DC, Scholey JW. Gender differences in the renal response to renin-angiotensin system blockade. J Am Soc Nephrol 17: 2554–2560, 2006. doi:10.1681/ASN.2005101095.
27. Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Law G, Desai M, Matthews DR; CANVAS Program Collaborative Group. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377: 644–657, 2017. doi:10.1056/NEJMoa1611925.
28. Ossani GP, Fischer PA, Caram SG, Dominguez GN, Monserrat AJ, Masnatta LD. Mild hyperhomocysteinemia promotes renal hemodynamic dysfunction without histopathologic changes in adult rats. Kidney Int 66: 1866–1872, 2004. doi:10.1111/j.1523-1755.2004.00960.x.
29. Petermann AT, Pippin J, Durvasula R, Pichler R, Hiromura K, Monkawa T, Couser WG, Shankland SJ. Mechanical stretch induces podocyte hypertrophy in vitro. Kidney Int 67: 157–166, 2005. doi:10. 1111/j.1523-1755.2005.00066.x.
30. Rajasekeran H, Lytvyn Y, Cherney DZ. Sodium-glucose cotransporter 2 inhibition and cardiovascular risk reduction in patients with type 2 diabetes: the emerging role of natriuresis. Kidney Int 89: 524–526, 2016. doi:10.1016/j.kint.2015.12.038.
31. Remuzzi G, Perico N, Macia M, Ruggenenti P. The role of renin-angiotensin-aldosterone system in the progression of chronic kidney disease. Kidney Int Suppl 68: S57–S65, 2005. doi:10.1111/j.1523-1755.2005. 09911.x.
32. Rodriguez D, Kapoor S, Edenhofer I, Segerer S, Riwanto M, Kipar A, Yang M, Mei C, Wüthrich RP. Inhibition of sodium-glucose cotransporter 2 with dapagliflozin in Han: SPRD rats with polycystic kidney disease. Kidney Blood Press Res 40: 638–647, 2015. doi:10.1159/000368540.
33. Sha S, Polidori D, Farrell K, Ghosh A, Natarajan J, Vaccaro N, Pinheiro J, Rothenberg P, Plum-Mörschel L. Pharmacodynamic differences between canagliflozin and dapagliflozin: results of a randomized, double-blind, crossover study. Diabetes Obes Metab 17: 188–197, 2015. doi:10.1111/dom.12418.
34. Skøtt P, Hommel E, Bruun NE, Arnold-Larsen S, Parving HH. Effects of acetazolamide on kidney function in type 1 (insulin-dependent) diabetic patients with diabetic nephropathy. Diabetologia 31: 806–810, 1988. doi:10.1007/BF00277481.
35. Skøtt P, Hommel E, Bruun NE, Arnold-Larsen S, Parving HH. The acute effect of acetazolamide on glomerular filtration rate and proximal tubular reabsorption of sodium and water in normal man. Scand J Clin Lab Invest 49: 583–587, 1989. doi:10.3109/00365518909089139.
36. Solini A, Rossi C, Mazzanti CM, Proietti A, Koepsell H, Ferrannini E. Sodium-glucose co-transporter (SGLT)2 and SGLT1 renal expression in patients with type 2 diabetes. Diabetes Obes Metab 19: 1289–1294, 2017. doi:10.1111/dom.12970.
37. Thomson SC, Rieg T, Miracle C, Mansoury H, Whaley J, Vallon V, Singh P. Acute and chronic effects of SGLT2 blockade on glomerular and tubular function in the early diabetic rat. Am J Physiol Regul Integr Comp Physiol 302: R75–R83, 2012. doi:10.1152/ajpregu.00357.2011.
38. Troyanov S, Wall CA, Miller JA, Scholey JW, Cattran DC; Toronto Glomerulonephritis Registry Group. Focal and segmental glomerulosclerosis: definition and relevance of a partial remission. J Am Soc Nephrol 16: 1061–1068, 2005. doi:10.1681/ASN.2004070593.
39. Tsuda A, Ishimura E, Ohno Y, Ichii M, Nakatani S, Mori K, Fukumoto S, Emoto M, Inaba M. Significant association of poor glycemic control with increased resistance in efferent arterioles–study of inulin and para-aminohippuric acid clearance in humans. Diabetes Res Clin Pract 104: 234–240, 2014. doi:10.1016/j.diabres.2014.01.030.
40. Vallon V, Gerasimova M, Rose MA, Masuda T, Satriano J, Mayoux E, Koepsell H, Thomson SC, Rieg T. SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice. Am J Physiol Renal Physiol 306: F194–F204, 2014. doi:10.1152/ajprenal.00520.2013.
41. Vallon V, Richter K, Blantz RC, Thomson S, Osswald H. Glomerular hyperfiltration in experimental diabetes mellitus: potential role of tubular reabsorption. J Am Soc Nephrol 10: 2569–2576, 1999.
42. Wang XX, Levi J, Luo Y, Myakala K, Herman-Edelstein M, Qiu L, Wang D, Peng Y, Grenz A, Lucia S, Dobrinskikh E, D’Agati VD, Koepsell H, Kopp JB, Rosenberg AZ, Levi M. SGLT2 protein expression is increased in human diabetic nephropathy: SGLT2 protein inhibition decreases renal lipid accumulation, inflammation, and the development of nephropathy in diabetic mice. J Biol Chem 292: 5335–5348, 2017. doi: 10.1074/jbc.M117.779520.
43. Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, Johansen OE, Woerle HJ, Broedl UC, Zinman B; EMPA-REG OUTCOME Investigators. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 375: 323–334, 2016. doi:10.1056/NEJMoa1515920.
44. Zhang Y, Thai K, Kepecs DM, Gilbert RE. Sodium-glucose linked cotransporter-2 inhibition does not attenuate disease progression in the rat remnant kidney model of chronic kidney disease. PLoS One 11: e0144640, 2016. doi:10.1371/journal.pone.0144640.
45. Zingerman B, Herman-Edelstein M, Erman A, Bar Sheshet Itach S, Ori Y, Rozen-Zvi B, Gafter U, Chagnac A. Effect of acetazolamide on obesity-induced glomerular hyperfiltration: a randomized controlled trial. PLoS One 10: e0137163, 2015. doi:10.1371/journal.pone.0137163.